StockData

Azitra vs Genelux

AZTR and GNLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AZTR and GNLX compare

Genelux is the larger company, worth 2.5 times as much as Azitra ($90.5M against $36.8M).

Genelux scores higher on the StockData Score (5 against 1 for Azitra), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAZTRGNLX
Size and price
Market cap$36.8M$90.5M
Share price$0.608$2.00
Change, 1 year67.0%−62.4%
Beta (5Y)–0.73
Employees13–
StockData Score
Total score15 (better)
Valuation score00
Growth score00
Performance score00
Health score15 (better)
Dividend score00
Valuation
P/B5.0× (better)5.6×
FCF yield−30.3% (better)−31.7%
Profitability
Return on equity−257%−178% (better)
Return on invested capital−1090%–
Financial health
Debt / equity–0.00
Interest coverage−1164.7×–
Current ratio4.86 (better)2.39
Altman Z-score−1.70 (better)−14.83
Piotroski F-score11
Dividends and buybacks
Buyback yield−14.8% (better)−20.8%
Shareholder yield−14.8% (better)−20.8%
Ownership
Held by institutions35.7%21.7%
Held by insiders9.6%7.7%
Insider net buying, 12 months–−$341K
Short interest, % of float0.56%10.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.